INVO Bioscience (INVO) Misses Q3 EPS by 9c

INVO Bioscience (NASDAQ: INVO) reported Q3 EPS of ($0.21), $0.09 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on INVO Bioscience (INVO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c